The 1873 Comstock Act makes it a crime to mail abortion drugs or medicine – raising legal questions about the law’s potential revival and influence over nationwide abortion laws.
Academic rigor, journalistic flair
Articles on FDA approval of mifepristone
Displaying all articles
As the government’s oldest consumer protection agency, the FDA has long butted up against drugmakers, activists and politicians. But undermining its work could be harmful to patient health and safety.
Mifepristone’s safety in medication abortions has been well established over more than two decades, but legal wrangling leaves the future of the drug hanging in the balance.
The Supreme Court’s ruling on mifepristone keeps the drug accessible for now, but its future is still in limbo.
Many people wonder how courts can rule in contradictory ways. But it happens relatively frequently.
If the ruling to reverse the use of mifepristone stands, it will not only severely restrict abortion access for women throughout the US – it will have far-reaching effects on health care.
Top contributors
-
Professor of Law, George Washington University
-
Associate Professor of Legal Studies and Political Science, UMass Amherst
-
Professor of Law, University of Virginia
-
Associate Professor of Obstetrics, Gynecology and Gynecologic Surgery, University of California, San Francisco
-
Professor of Law, Wake Forest University
-
Associate Professor of Family Medicine, School of Medicine, University of Washington
